CCR9

CCR9 (C-C chemokine receptor type 9) is a G protein-coupled receptor that mediates the migration and localization of lymphocytes, particularly thymocytes, to the small intestine^[1][2]. Mechanistically, CCR9 interacts with its ligand, chemokine ligand 25 (CCL25), to direct effector and regulatory T-cell trafficking, which is critical for maintaining intestinal immune homeostasis^[2]. In disease models, CCR9 deficiency or blockade in TNFΔARE mice exacerbates Crohn's-like ileitis due to reduced recruitment of CD4⁺/CD25⁺/FOXP3⁺ and CD8⁺/CD103⁺ T regulatory cells, indicating its essential role in controlling intestinal inflammation^[2]. Compared with related chemokine receptor isoforms such as CCR2A and CCR2B, CCR9 exhibits tissue-specific expression and a unique gut-homing function, distinguishing it from receptors primarily involved in systemic monocyte recruitment^[3][4]. Pharmacologically, selective small-molecule CCR9 antagonists such as vercirnon and CCX507 bind intracellular allosteric sites, preventing G-protein coupling, and have been explored for treating inflammatory bowel disease, although high doses are required to achieve effective receptor blockade^[5][6]. CCR9 inhibitors in combination with integrin α4β7 blockade show synergistic protective effects in colitis models, highlighting potential combinatorial therapeutic strategies^[5][7].